Gulf Pharmaceutical Industries (JULPHAR)

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) registered accumulated losses valued at AED 346.70 million as of 31 December 2023. The incurred accumulated losses represent 30% of the company’s paid-up capital, according to a bourse …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) shifted to net losses attributable to the equityholders amounting to AED 83.40 million in the first nine months (9M) of 2023. The negative results were compared to net profits worth …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) swung to net losses attributable to the owners valued at AED 44.10 million in the first half (H1) of 2023, versus profits of AED 6.30 million in H1-22. The revenues from contracts with …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) turned to net losses attributable to the shareholders worth AED 2.90 million in the first quarter (Q1) of 2023. The incurred net losses were against profits valued at AED 1.50 million …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) announced, on 9 February, the resignation of Essam Mohamed from his position as the CEO of the company. Julphar elaborated that Mohamed left the firm as he will join another company, …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) logged net profits attributable to the owners worth AED 10.40 million in the first nine months (9M) of 2022, down from AED 103.20 million in 9M-21. Revenue from contracts with …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has achieved net profits attributable to the equity holders of AED 1.5 million in the first quarter (Q1) of 2022, against net losses of AED 23.9 million in the same quarter of 2021, …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has achieved net profits attributable to the equity holders of AED 64.4 million in 2021, against net losses of AED 293.2 million in 2020, according to the company's consolidated …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has reached an exclusive license and production agreement with Quantum Genomics, a France-based biopharmaceutical company, to market and produce firibastat. Through its manufacturing …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has incurred accumulated losses of AED 183.1 million as of the third quarter (Q3) of 2021, representing 16% of the capital. The losses are driven by the temporary suspension of export …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has entered into an agreement to sell its wholly-owned subsidiary, Dubai-based Gulf Inject, to GlobalOne Healthcare Holding, the healthcare division of Yas Holding in Abu Dhabi. The …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) registered AED 49.9 million in profits during the first half (H1) of the year, compared with losses of AED 83.2 million in H1-20. The company attributed turning profitable to the …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has entered into an agreement to fully acquire Planet Pharmacies, one of the leading pharmaceutical distributors in the UAE, Saudi Arabia, and the Sultanate of Oman. Julphar, which …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has sold its 51% stake in Alpha Pharma. Expected to be completed in the third quarter (Q3) of 2021, the transaction is expected to reduce 10% to 12% of Julphar's consolidated total …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has entered into a manufacturing agreement with G42 Medications Trading to produce the coronavirus (COVID-19) vaccines from China's Sinopharm. The commercial production of the …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) posted AED 83.2 million accumulated losses as of the end of the second quarter (Q2) of 2020, representing 12.7% of the capital. The accumulated losses are driven by the temporary …

Abu Dhabi – Mubasher: The AED 500 million rights issue of Gulf Pharmaceutical Industries (Julphar) has been oversubscribed 2.3 times to settle at AED 1.14 billion on application which closed on 12 July. The net proceeds from the rights issue will …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has launched a rights issue to raise AED 500 million and improve its capital position and debt profile. By raising AED 500 million, the company will finance its turnaround plan and put …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) incurred AED 62.5 million in net losses attributable to shareholders during the first quarter of 2020, down from AED 89.1 million in the year-ago period. Net sales fell to AED 114.6 …

Abu Dhabi – Mubasher: The Saudi Food and Drug Authority (SFDA) has lifted the temporary suspension on the exports of Gulf Pharmaceutical Industries (Julphar) to Saudi Arabia. Following a ban for 20 months, Julphar's exports to Saudi Arabia will be …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) plans to decrease the share capital by AED 503.274 million by canceling a number of the company's shares. With the capital reduction, Julphar seeks to write off accumulated losses …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries Company (Julphar) has posted a 163.5% year-on-year loss hike during the third quarter of the fiscal year 2019. The company’s loss surged to AED 201.3 million in Q3-19, compared to AED 76.4 …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) announced it would authorize the use of AED 184.80 million of the company’s voluntary reserve, as well as AED 376.90 million of the statutory reserve to offset accumulated losses of …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) announced that its Jerome Carle who performs as its CEO has tendered his resignation. The board of Julphar has accepted the resignation of Carle, according to a bourse disclosure to …

Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries Company (Julphar) has suffered losses during the second quarter of 2019, against profits achieved in the corresponding period last year. The company incurred losses attributed to the owners of …